$AVXL

ANAVEX LIFE SCIENCES CORP.

No enriched coverage for $AVXL in the last 7 days.

No SEC Form 4 filings for $AVXL in the last 30 days.

Med

Autistic adults had up to 8x dementia rates in research Anavex cites

Anavex Life Sciences announced new scientific findings linking autism spectrum disorder (ASD) and Alzheimer’s disease (AD) through shared biological mechanisms like autophagy dysfunction and synaptic pruning deficits. The company cites epidemiological research indicating autistic adults may have up to 8 times higher dementia rates. These findings support Anavex's intent to advance blarcamesine, a SIGMAR1 activator, into pivotal clinical studies, building on its demonstrated effects in previous trials for Alzheimer's, Rett syndrome, and Parkinson's disease dementia.

Anavex Life Sciences to Present at the Citizens Life Sciences Conference

Anavex Life Sciences Corp. announced that its President & CEO, Christopher U Missling, PhD, will present at the Citizens Life Sciences Conference on March 10, 2026, at 11:55 AM (ET). The company is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for various neurological disorders including Alzheimer's disease and Parkinson's disease. Anavex highlights its lead drug candidate, ANAVEX®2-73 (blarcamesine), which has undergone several clinical trials for Alzheimer's, Parkinson's, and Rett syndrome, and also mentions ANAVEX®3-71 for Alzheimer's disease.

Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference

Anavex Life Sciences (Nasdaq: AVXL) CEO, Christopher U Missling, PhD, is scheduled to present at the Citizens Life Sciences Conference on Tuesday, March 10, 2026, at 11:55 AM ET. The presentation will cover the company's clinical-stage CNS programs, including therapies for Alzheimer's, Parkinson's, schizophrenia, Rett syndrome, and other neurodegenerative and rare diseases. This event is part of Anavex's ongoing investor relations efforts to increase awareness of its pipeline.